health technology assessments

Same Survival and Toxicity With APBI and WBI for Breast Cancer

05/04/2016

JCP Editors

Accelerated partial breast irradiation (APBI) leads to the same rates of survival and toxicity as whole breast irradiation (WBI) while also producing significantly better cosmetic results, according to phase 3 trial...

...

05/04/2016

Journal of Clinical Pathways

SBRT for Patients With NSCLC Linked to Higher Rates of Non-Cancer Death

05/04/2016

JCP Editors

Using stereotactic body radiation therapy (SBRT) to treat patients with non-small cell lung cancer (NSCLC) may slightly increase the risk of dying from a cause other than cancer, according to research presented at...

Using...

05/04/2016

Journal of Clinical Pathways

Research in Review

Radiotherapy Plus Surgery Better for Older Patients With Soft-Tissue Sarcoma

04/29/2016

JCP Editors

Age may be a significant determinant of the effectiveness of radiotherapy in patients with soft-tissue sarcoma undergoing surgery, according to a recent study. While the survival rates for early-stage, soft-tissue...

Age...

04/29/2016

Journal of Clinical Pathways

Research in Review

Blood Biopsy Test Ready for Use in Patients With NSCLC

04/14/2016

JCP Editors

A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the...

A...

04/14/2016

Journal of Clinical Pathways

Research in Review

PET-Guided Chemotherapy Improves Progression-Free Survival in Patients With Hodgkin Lymphoma

04/12/2016

JCP Editors

Using positron emission tomography (PET) imaging to guide chemotherapy may help to improve progression-free survival (PFS) for patients with advanced Hodgkin lymphoma (HL), according to a study conducted by the...

Using...

04/12/2016

Journal of Clinical Pathways

Research in Review

Novel Precision Medicine Tool Effective for Tracking Mutation-Specific Patient Outcomes

04/08/2016

JCP Editors

Researchers have developed a novel tool for calculating and displaying the survival statistics of patients with cancer depending on their genetic profile, which could help practitioners to better track...

...

04/08/2016

Journal of Clinical Pathways

Research in Review

Patients With Prostate Cancer Do Not Benefit From Higher Doses of Radiotherapy

04/06/2016

JCP Editors

While advances in technology have allowed physicians to administer higher doses of radiation to treat prostate cancer, results from a recent study have revealed that escalating dose may not help patients in the long...

While...

04/06/2016

Journal of Clinical Pathways

Research in Review

Co-Testing a More Cost-Effective Screening Strategy for Cervical Cancer Than HPV Primary

04/01/2016

JCP Editors

A model developed using data from health care databases and published literature has found that Pap plus human papillomavirus (HPV) mRNA testing that includes genotying for HPV 16 and 18 may be a more effective...

A...

04/01/2016

Journal of Clinical Pathways

Research in Review

Gene-Expression Test Cost-Effective for Determining Unknown Tumor Origins

03/31/2016

JCP Editors

The 2000-gene-expression profiling (GEP) test may be a more cost-effective option than current strategies for identifying tumor origin in patients with cancer of unknown primary (CUP), a recent study...

The...

03/31/2016

Journal of Clinical Pathways

Research in Review

Hypofractionation Leads to Greater Toxicity in Patients with Prostate Cancer

03/29/2016

JCP Editors

A new study has failed to demonstrate hypofractionated radiotherapy as a non-inferior option to fractionated radiotherapy for patients with intermediate- or high-risk prostate cancer. In patients with genitourinary...

A new...

03/29/2016

Journal of Clinical Pathways